SEOM‑GEMCAD‑TTD clinical guidelines for anal cancer (2025) - Clinical and Translational Oncology
Chemoradiotherapy with 5‑FU and mitomycin C (MMC) is the standard of care for early and locally advanced disease, while combination chemotherapy with a platinum‑containing compound and taxanes is the treatment of choice for metastatic disease.
Anal cancer is rare but increasingly common, currently accounting for 2% of all digestive neoplasms. Some 50% of anal cancers are diagnosed at the localized stage, 29% as locoregional disease, and 12% as metastatic disease. When clinical suspicion of anal cancer exists, histological confirmation, correct local staging with MRI and distant staging with thoraco‑abdominal CT, and management by a multidisciplinary team are mandatory. Chemoradiotherapy with 5‑FU and mitomycin C (MMC) is the standard of care for early and locally advanced disease, while combination chemotherapy with a platinum‑containing compound and taxanes is the treatment of choice for metastatic disease.
This sentence identifies the recommended standard therapy for both early/locoregional and metastatic anal cancer, guiding clinicians in selecting the appropriate treatment regimen.
Bizonyítékszint: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Kapcsolódó jelek
- Clinical Outcomes, Patterns of Failure, and Salvage Therapies of a Large Modern Cohort of Patients With Anal Squamous Cell Carcinoma Treated With Definitive-Intent Intensity‑Modulated Radiation Therapy
- Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer
- Advancements in Immunotherapy for Anal Cancer Treatment
- Background and Current Treatment of Squamous Cell Carcinoma of the Anus
- Genotyping and Cytology Co-Testing for Anal Cancer Screening: Exploratory Evaluation of Cumulative HPV Genotype Burden